The industry’s attention is focused on whether the insurance reimbursement discussions for the acute myeloid leukemia drug ‘Mylotarg’ will make progress this time.

According to the industry sources, Pfizer Korea’s acute myeloid leukemia (AML) drug ‘Mylotarg (gemtuzumab ozogamicin)’ is set to be submitted to the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee. However, it is not yet confirmed whether the agenda it will be presented in November.

Mylotarg’s reimbursement agenda was deliberated by HIRA’s Cancer Disease Review Committee in May 2022 but was unable to set reimbursement standards then. It passed the CDDC review in October last ye